Luke, J. J., Sweis, R. F., Hecht, J. R., Schneider, R., Stein, M. N., Golan, T., Yap, T. A., Khilnani, A., Huang, M., Zhao, R., Jemielita, T., & Patel, S. P. (2025). Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research, 31(7), 1233–1242. https://doi.org/10.1158/1078-0432.ccr-24-2824

Franzblau, L. E., Fuleihan, R. L., Cunningham-Rundles, C., & Wysocki, C. A. (2023). CVID-Associated Intestinal Disorders in the USIDNET Registry: An Analysis of Disease Manifestations, Functional Status, Comorbidities, and Treatment. Journal of Clinical Immunology, 44(1). https://doi.org/10.1007/s10875-023-01604-6

Leeman-Neill, R. J., Song, D., Bizarro, J., Wacheul, L., Rothschild, G., Singh, S., Yang, Y., Sarode, A. Y., Gollapalli, K., Wu, L., Zhang, W., Chen, Y., Lauring, M. C., Whisenant, D. E., Bhavsar, S., Lim, J., Swerdlow, S. H., Bhagat, G., Zhao, Q., … Basu, U. (2023). Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression. Nature Genetics, 55(12), 2160–2174. https://doi.org/10.1038/s41588-023-01561-1

Chen, X., Li, Y., Zhu, F., Xu, X., Estrella, B., Pazos, M. A., McGuire, J. T., Karagiannis, D., Sahu, V., Mustafokulov, M., Scuoppo, C., Sánchez-Rivera, F. J., Soto-Feliciano, Y. M., Pasqualucci, L., Ciccia, A., Amengual, J. E., & Lu, C. (2023). Context-defined cancer co-dependency mapping identifies a functional interplay between PRC2 and MLL-MEN1 complex in lymphoma. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39990-5

Ford, M., Orlando, E., & Amengual, J. E. (2023). EBV Reactivation and Lymphomagenesis: More Questions than Answers. Current Hematologic Malignancy Reports, 18(6), 226–233. https://doi.org/10.1007/s11899-023-00708-5

Cuzzo, B., Lipsky, A., & Cherng, H.-J. J. (2023). Measurable Residual Disease Monitoring in Lymphoma. Current Hematologic Malignancy Reports, 18(6), 292–304. https://doi.org/10.1007/s11899-023-00715-6

Olén, O., Smedby, K. E., Erichsen, R., Pedersen, L., Halfvarson, J., Hallqvist-Everhov, Å., Bryder, N., Askling, J., Ekbom, A., Sachs, M. C., Sørensen, H. T., Ludvigsson, J. F., Olsson, M., Myrelid, P., Hjortswang, H., Bengtsson, J., Strid, H., Andersson, M., Jäghult, S., … Karling, P. (2023). Increasing Risk of Lymphoma Over Time in Crohn’s Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study. Clinical Gastroenterology and Hepatology, 21(12), 3132–3142. https://doi.org/10.1016/j.cgh.2023.04.001

Lee, H., Choi, M., Siddiqi, T., Rhodes, J., Wierda, W., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J., Leslie, L., Goldenberg, A., Chung, G., Breitmeyer, J., Yazji, S., Shih, T., Wang, M., Jamieson, C., & Kipps, T. (2023). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Hematological Oncology, 41(S2), 587–589. Portico. https://doi.org/10.1002/hon.3164_440

Amengual, J. E., Reagan, P., Li, H., Saeed, H., Vaidya, R., Unger, J. M., Danilov, A., LeBlanc, M., Friedberg, J. W., & Smith, S. M. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology, 41(S2), 842–843. Portico. https://doi.org/10.1002/hon.3166_ot22

Pal, I., Scotto, L., Sabzevari, A., Kinahan, C., Fox, T. E., Feith, D. J., Marchi, E., Loughran, T. P., & O’Connor, O. A. (2023). Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma. Hematological Oncology, 41(S2), 313–314. Portico. https://doi.org/10.1002/hon.3164_220

Gounder, M. M., Bauer, T. M., Schwartz, G. K., Weise, A. M., LoRusso, P., Kumar, P., Tao, B., Hong, Y., Patel, P., Lu, Y., Lesegretain, A., Tirunagaru, V. G., Xu, F., Doebele, R. C., & Hong, D. S. (2023). A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. Journal of Clinical Oncology, 41(9), 1714–1724. https://doi.org/10.1200/jco.22.01285

Ricard, F., Barrington, S., Korn, R., Brueggenwerth, G., Trotman, J., Cheson, B., Salles, G., Schwartz, L., Goldmacher, G., Jarecha, R., Narang, J., Broussais, F., Galette, P., Liu, M., Bajpai, S., Perlman, E., Gillis, J., Smalberg, I., Terve, P., … Schmid, A. (2022). Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical). Journal of Nuclear Medicine, 64(2), 239–243. https://doi.org/10.2967/jnumed.122.264124

Ricard, F., Cheson, B., Barrington, S., Trotman, J., Schmid, A., Brueggenwerth, G., Salles, G., Schwartz, L., Goldmacher, G., Jarecha, R., Narang, J., Broussais, F., Galette, P., Liu, M., Bajpai, S., Perlman, E., Gillis, J., Smalberg, I., Terve, P., … Korn, R. (2022). Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical). Journal of Nuclear Medicine, 64(1), 102–108. https://doi.org/10.2967/jnumed.122.264106

Ryu, Y. K., & Amengual, J. E. (2022). Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma. The Lancet Haematology, 9(7), e463–e465. https://doi.org/10.1016/s2352-3026(22)00169-7

Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. de O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., Chadburn, A., Chan, J. K. C., Cheuk, W., Chng, W.-J., Choi, J. K., Chuang, S.-S., Coupland, S. E., Czader, M., Dave, S. S., … Xiao, W. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 36(7), 1720–1748. https://doi.org/10.1038/s41375-022-01620-2